These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14656277)

  • 1. The role of anthracyclines in second-line therapy of ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2003; 13 Suppl 2():178-84. PubMed ID: 14656277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal anthracycline treatment for ovarian cancer.
    Markman M; Gordon AN; McGuire WP; Muggia FM
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):91-105. PubMed ID: 15717739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].
    du Bois A; Lück HJ; Pfisterer J; Meier W; Bauknecht T
    Zentralbl Gynakol; 2000; 122(5):255-67. PubMed ID: 10857212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.
    Rakowski JA; Ahmad S; Holloway RW
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):31-40. PubMed ID: 22149430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
    Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pegylated liposomal doxorubicin in ovarian cancer treatment].
    Nowak-Markwitz E
    Ginekol Pol; 2009 Aug; 80(8):615-9. PubMed ID: 19824461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
    Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
    Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
    Ledermann JA; Wheeler S
    Cancer Invest; 2004; 22 Suppl 2():2-10. PubMed ID: 15573740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized single-agents trials in recurrent epithelial ovarian cancer.
    Sessa C; Marsoni S
    Int J Gynecol Cancer; 2005; 15 Suppl 3():247-51. PubMed ID: 16343240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
    Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
    Power P; Stuart G; Oza A; Provencher D; Bentley JR; Miller WH; Pouliot JF
    Gynecol Oncol; 2009 Sep; 114(3):410-4. PubMed ID: 19520420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
    Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
    Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting.
    Petru E; Reinthaller A; Angleitner-Boubenizek L; Schauer C; Zeimet A; Dirschlmayer W; Medl M; Stummvoll W; Sevelda P; Marth C
    Wien Klin Wochenschr; 2010 Nov; 122(21-22):649-52. PubMed ID: 21072604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
    Marth C
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin combined with carboplatin: a rational treatment choice for advanced ovarian cancer.
    Pignata S; Lauraine EP; du Bois A; Pisano C
    Crit Rev Oncol Hematol; 2010 Jan; 73(1):23-30. PubMed ID: 19782576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.